Foghorn Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, showing collaboration revenue of $16.1 million and a net loss of $7.2 million. The company holds approximately $168 million in cash equivalents, providing a runway into the first half of 2028. Clinically, the Phase 1 dose-escalation trial for FHD-909 (LY4050784) is advancing as planned with non-small cell lung cancer as the primary target population. The company also announced that IND submissions are targeted for 2027 for a novel oral small molecule in immunology and inflammation, as well as its selective EP300 degrader program. Foghorn Therapeutics operates in the biotechnology industry, developing medicines targeting chromatin biology.